Multimodal imaging of tumor response to sorafenib combined with radiation therapy: comparison between diffusion‐weighted MRI, choline spectroscopy and 18F‐FLT PET imaging. (13th March 2013)

• Record Type: Journal Article
• Authors: Karroum, Oussama; Mignion, Lionel; Kengen, Julie; Karmani, Linda; Levêque, Philippe; Danhier, Pierre; Magat, Julie; Bol, Anne; Labar, Daniel; Grégoire, Vincent; Bouzin, Caroline; Feron, Olivier; Gallez, Bernard; Jordan, Bénédicte F.
• Is Part Of: Contrast media & molecular imaging. Volume 8:Number 3(2013:May/Jun.)
• Page Start: 274
• Page End: 280
• Publication Date: 2013-03-13
• Subjects: sorafenib -- radiotherapy -- DW‐MRI -- choline spectroscopy -- 18F‐FLT PET imaging; Diagnostic imaging -- Periodicals; Magnetic resonance imaging -- Periodicals; Contrast media (Diagnostic imaging) -- Periodicals; Contrast Media -- Periodicals; Diagnostic Imaging -- Periodicals; Substances de contraste -- Périodiques; Diagnostics moléculaires -- Périodiques; Imagerie médicale; Substance de contraste; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.0754
• DOI: 10.1002/cmmi.1525
• Languages: English
• ISSNs: 1555-4309

Abstract

Abstract : The purpose of this study was to determine the value of different imaging modalities, that is, magnetic resonance imaging/spectroscopy (MRI/MRS) and positron emission tomography (PET), to assess early tumor response to sorafenib with or without radiotherapy. Diffusion‐weighted (DW)‐MRI, choline 1 H MRS at 11.7 T, and 18 F‐FLT PET imaging were used to image fibrosarcoma (FSaII) tumor‐bearing mice over time. The imaging markers were compared with apoptosis cell death and cell proliferation measurements assessed by histology. Anti‐proliferative effects of sorafenib were evidenced by 1 H MRS and 18 F‐FLT PET after 2 days of treatment with sorafenib, with no additional effect of the combination with radiation therapy, results that are in agreement with Ki67 staining. Apparent diffusion coefficient calculated using DW‐MRI was not modified after 2 days of treatment with sorafenib, but showed significant increase 24 h after 2 days of sorafenib treatment combined with consecutive irradiation. The three imaging markers were able to show early tumor response as soon as 24 h after treatment initiation, with choline MRS and 18 F‐FLT being sensitive to sorafenib in monotherapy as well as in combined therapy with irradiation, whereas DW‐MRI was only sensitive to the combination of sorafenib with radiotherapy. Copyright © 2013 John Wiley & Sons, Ltd. Abstract : DW‐MRI, choline 1 H MRS at 11.7 T and 18 F‐FLT PET imaging were used to image fibrosarcoma tumor‐bearing mice. The imaging markers were compared with apoptosis cell death and cell proliferation measurements assessed by histology. All imaging markers were able to show early tumor response after 2 days of treatment: choline MRS and 18 F‐FLT were sensitive to sorafenib in monotherapy as well as in combined therapy with irradiation, whereas DW‐MRI was only sensitive to the combination of sorafenib with radiotherapy.